The two companies will jointly develop production devices and radiopharmaceuticals based on photoredox synthesis technology and promote their marketization. The collaboration, leveraging LED's patented photocatalytic radiofluorination technology and Premium Imaging's expertise in radiopharmaceutical development and commercialization, aims to provide new and better treatment options for patients worldwide.
The MoU was signed during the 2024 Annual Meeting of Society of Nuclear Medicine and Molecular Imaging (SNMMI2024) in Toronto. PI Chief Operating Officer Steve Tang (left), LED Co-founder Zibo Li (middle), and LED Co-founder David Nicewicz (right).
"Nuclear medicine is a rapidly growing market due to numerous unmet patient needs,” said Zibo Li, PhD, LED Co-founder, Professor of Radiology, and Director of the Cyclotron Facility at UNC Chapel Hill. “Doctors can face the dilemma of choosing between high-quality PET tracers for accurate diagnosis, which require complex and difficult on-site preparation, and tracers with easier on-site production that offer only acceptable imaging quality. Therefore, it is urgent for us to develop equipment and products with both simple synthesis procedures and high imaging quality. Our photoredox radiolabeling technology provides an innovative solution for these needs.”
Li added, “ We are very pleased to collaborate with Premium Imaging combining their expertise in clinical translation and commercialization with our cutting-edge technology. Together, we aim to bring our products to market in the most efficient and scientifically solid way, so that more patients can benefit from new radiopharmaceuticals as soon as possible. “
"LED Radiofluidics is excited to initiate this joint venture with Premium Imaging to bring our photoredox radiolabeling technology to the market to ultimately improve imaging and patient outcomes," said David Nicewicz, PhD, LED Co-founder. "Importantly, advancements in organic chemistry and catalysis have made this new reaction technology possible, and we see this as the start of a very fruitful partnership."
Steve Tang, Chief Operating Officer of PI, said: " LED Radiofluidics's patented photocatalytic radiofluorination technology is an innovative technology that will create important and differentiated radiopharmaceuticals. We are very confident in the equipment and radiopharmaceuticals developed by LED's patented technology platform. From the existing preclinical data, it has a stable and high-quality imaging, and the preparation process is convenient, which is excellent to solve the pain points of clinicians. We look forward to working with LED Radiofluidics and using their products to bring new diagnosis agents, therapies and new hope to patients worldwide.”
About LED Radiofluidics Corp.
LED Radiofluidics Corp is an early-stage biopharmaceutical company founded in 2020 by Dr. Zibo Li and Dr. David Nicewicz at UNC-Chapel Hill. The company specializes in developing innovative molecular imaging agents using a patented photoredox radiolabeling technology. LED is dedicated to creating accessible photoredox radiolabeling devices/supports to promote broader adoption. Their leading project focuses on a radioactive PET tracer and its synthesis device based on this advanced technology platform.
About Premium Imaging Inc.
Premium Imaging Inc., a leading radiopharmaceutical biotechnology company, is dedicated to the development, production and global supply of precision diagnostics and radiotherapeutics for hard-to-treat disease. By leveraging our radiopharmaceutical expertise, extensive experience in transformation and commercialization, and established global networks, we strive to provide patients with earlier diagnosis and deliver effective targeted therapies to improve clinical outcome and life quality.
